OPEN END TURBO OPTIONSSCHEIN LONG - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 14:26:40 2024-06-28 EDT | After market 15:58:35 | |||
| 14.48 EUR | +0.42% |
|
13.93 | -3.80% |
| Current month | +18.29% | ||
| 1 month | +9.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 14.48 | +0.42% |
| 24-06-27 | 14.42 | -0.35% |
| 24-06-26 | 14.47 | +0.91% |
| 24-06-25 | 14.34 | -1.71% |
| 24-06-24 | 14.59 | +5.19% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 02:26 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GX9B68 |
| ISIN | DE000GX9B682 |
| Date issued | 2022-09-06 |
| Strike | 321.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.01 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.41 € |
|---|---|
| Lowest since issue | 0.219 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
